drugset / Trial / NCT00836576

Benazepril HCl 40 mg Tablets, Fasting

NCT00836576

Phase 1 Completed 40 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this randomized, single-dose, two-way crossover evaluation is to compare the oral bioavailability of a test benazepril HCl formulation (TEVA Pharmaceutical Industries Ltd.) to an equivalent oral dose of the commercially available benazepril HCl (Lotensin®, Novartis Pharmaceuticals Corporation) in a test population of 40 adults under fasting conditions.

Timeline

Start
2001-02
Primary completion
2001-03
Completion
2001-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Benazepril Unknown 40 mg Oral

Indications

No indication recorded.